~EXPECTING NEWS~

[StkMktPirate]

CVSL Expecting News-->UPDATED COMPILATION CVSL DD->

Insider Purchase 125,000,000 Shares!

Thomas DiCicco purchased 125,000,000 Shares of CVSL and it appears as if there may be something big taking place here.

500 Mil Shares are authorized and 196,900,00 OS



ABOUT: Thomas DiCicco
President, Director and Chief Executive Officer
Cardio Vascular Medical Device Corp
Haifa
Sector: HEALTHCARE / Medical Instruments & Supplies
Officer since May 2011

60 Years Old
On May 17, 2011, Thomas DiCicco, Thomas DiCicco became our president and director. Mr. Thomas DiCicco has served as Chief Executive Officer of Infrared Sciences Corp. since the Company?s formation in September 1999. Prior to founding the Infrared Sciences (and again presently), he was a Founder and Vice President of Globecomm Systems Inc., a public satellite communications company [NASDAQ: GCOM]. Mr. DiCicco has over 41 years of experience in military and commercial electronics with over 33 years of experience specifically in the satellite telecommunications engineering field. From 1978 to 1994, Mr. DiCicco was responsible for the design and development of satellite communications earth terminals and products, while employed by Comtech Laboratories and then with Satellite Transmission Systems. During prior employment at Airborne Instruments Laboratory, from 1970 to 1978, Mr. DiCicco gained an extensive background in military electronic systems, including digital signal processing systems, IFF and microwave landing systems. Mr. DiCicco holds a Bachelor of Science in Electrical Engineering from Hofstra University and is a US Patent holder. We believe that Mr. DiCicco?s experience in electrical engineering will bring valuable experience to the development of our technologies and planned products.

http://people.forbes.com/profile/thomas-dicicco/155445

Thomas DiCicco is involved in the Development of DIGITAL INFRARED IMAGING IN ENHANCED BREAST CANCER DETECTION AND MONITORING known as the Sentinel Breastscan.
http://www.iamtonline.org/pdfs/breast.pdf


Could this be coming to CVSL????

The Sentinel BreastScan, an adjunctive non-invasive breast cancer detection system, has undergone clinical testing at the Cornell Weill Medical College of Cornell University in New York City. The results of the study were published in the American Journal of Surgery this past October 2008. Thomas DiCicco commented that "that the results were excellent, with sensitivities approaching 97%, and reinforced the tremendous potential of this non-invasive technology". He added "that the Cornell study was the only recent study conducted in a prestigious academic institution of breast cancer detection utilizing state-of-the-art digital infrared imaging, and will be a major factor in the acceptance and expansion of the Sentinel BreastScan within main-stream medicine". The Sentinel BreastScan is unlike any other infrared system; being a fully automated dynamic test, employing artificial intelligence software, and a providing a fully interpreted real-time test report to the doctor. DiCicco added, "All women of any age stand to benefit from this technological leap forward, by providing their doctor with physiologic breast health data with a low cost, painless, non-invasive test; data that is not available from any other breast cancer test today."


Sentinel BreastScan- Early Breast Cancer Detection- FDA Approved (April 19th, 2011)

Infrared Sciences Corporation has developed a screening process, the Sentinel BreastScan, which employs digital infrared imaging to detect breast cancer with a high degree of accuracy and at a very early stage. The product is an adjunctive1 test that physicians use to screen for and isolate pre-cancerous and cancerous tumors. The company provides the systems to gynecologists, radiologists, medical oncologist, hospitals, third-party imaging centers, and women’s health centers for use as an adjunctive screening tool to mammography. When used in a program that combines infrared with other modalities, the Sentinel BreastScan is expected to significantly increase the early detection of breast cancer. The Sentinel BreastScan was granted FDA 510(k) approval in 2004 and it’s European Union CE Mark in 2006.

http://www.gobreastcancer.info/archives/sentinel-breastscan-early-breast-cancer-detection-fda-approved.html


Sentinel Breastscan featured on CBS and ABC (April 30th, 2011)

http://www.gobreastcancer.info/archives/sentinel-breastscan-featured-on-cbs-and-abc-early-breast-cancer-detection.html


IN CVSL 8-K : We intend to continue to engage in the pursuit and development of patented and non-patented technologies involving medical devices, and/or other devices or applications that involve, advanced imaging technology, signal processing, and image processing.

What is Sentinel BreastScan Technology?---- >Sentinel BreastScan is a painless, touchless, non-invasive procedure offered to women of any age. The technology is based on advanced digital infrared imaging that is combined with sophisticated software employing artificial intelligence techniques



26 MAY 2011 SEC Filing Out- PRE 14 C->


Cardio Vascular Medical Devices will be changed to Computer Vision Systems Laboratories Corp.


With ticker symbol change to follow

http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=7960954

In this filing the stated Reasons for the Name Change are
We believe that this name change provides a more appropriate description of our business than our current name and will provide the investing public and business community with a better understanding of our business plan. The trading symbol for our Common Stock will also be changed, but this new symbol is not available to us as of the preparation date of this Information Statement. The Board believes the name of Cardio Vascular Medical Devices should be changed to Computer Vision Systems Laboratories Corp. to avoid any confusion with companies with similar names domiciled in the state of Florida where we will be domiciled on the Effective Date. Additionally, our Board believes that the name Computer Vision Systems Laboratories Corp. better reflects our planned operations which are not limited to Cardio Vascular technologies and which may include devices for the detection of breast cancer and other diseases.

name change effective on June 6, 2011
also share structure reorganization
A/S becomes 500m of which 10m will be preferred



I think enough has been said and there will be plenty more PR to follow!!

Stay tuned for more!!!




ALSO:


Cardio Vascular Medical Device Corp holds the US patent for the innovative Steerable Guidewire applicable for all PCTA (angioplasty) procedures. The CVSL guidewire surpasses the limitations of the guidewires that are currently being used. Their technology could easily become the gold standard, as the guidewire of choice for heart surgeons around the world, with a potential market of over $500 million per year.

CVSL’s annual potential addressable market exceeds of $500 mil worldwide.

CVSL’s technology could be used in approximately 3 million procedures per year! Global demand for steerable guidewires exceeds 4.5 million annually.

This is an ENORMOUS market! Thousands of heart surgeries are performed every day in the United States! Millions of dollars are spent on similar devices.

With a superior patented product, CVSL has a tremendous opportunity to flourish in this rich market.


Market The market for peripheral vascular devices is expected to grow at a CAGR of 9.1% from 2008 to 2015. In 2009, annual spending in the US market for peripheral vascular devices was estimated to be over $2.8 billion. The current estimate of the guidewire market is somewhere around $150 million.

From 1996-2006, annual cardiovascular operations & procedures increased by 30% from 5.4 million to 7.2 million. Included in the total number are 1.3 million percutaneous coronary intervention procedures.

Strong growth throughout the interventional cardiology market is expected to occur due to several factors. These include improved products and procedures allowing for the treatment of patients that were previously thought of as untreatable; reimbursement by insurance companies¸ resulting in more procedures taking place and higher revenues; and an increased numbers of stents used in each procedure.

Product CVSL Solution • Improved performance.

• Enables the neurosurgeon to reach the specified location much quicker.

• Tip bent according to the force applied to it.

• Made of super elastic NiTi (nickel titanium), PTFE (Teflon), coated coil and 0.15 mm wire.

• The wire is attached to a soft tip.

• Distral end of the coil is treated so that when the inner wire is pulled the tip buckles and bends accordingly.

• Available in various sizes.

• Cost efficiency for both the patient and health care provider.

Business Strategy CVSL’s principal business plan is to develop a prototype and then manufacture and market the product and seek third party entities interested in licensing the rights to manufacture their product.

Once they have a valid prototype, they will apply for an IRB to start conducting clinical trials, of which based on these results the Company, in conjunction with the third party manufacturers, will apply for FDA approval.

Once FDA approval is received, the Company will seek to license the related technology to medical companies, strategic partners and / or manufacture the products for medical clinics and / or hospitals.



GUYS THIS IS HUGE!!!!!!

LAST 5 SEC FILINGS
PRE 14C http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=7960954
10-Q http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=7948884
8-K http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=7944586
SC 13D http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=7942523
3 http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=7941981



JER1


CVSL